Sean has more than 15 years of experience in pricing and reimbursement while at Amgen.
He has launched several products globally; and developed pricing and market access strategies for pharmaceutical products across the lifecycle. He has been a thought leader in developing strategies and tactics to combat International Reference Pricing; and providing advice to companies about what they can do to better prepare for reference pricing.  He is the author of several publications in clinical and health economics journals and has been involved in the development of pricing defense strategies for several of the early Biosimilars launched in Europe. He was an early advocate in instituting value-based selling programs to bring pricing and Key Account Management teams closer together to foster shared goals in pricing execution.  Sean is currently an Adjunct Assistant Professor at the University of Southern California in the Titus School of Pharmacy and Health Policy. Sean is passionate about introducing profit enhancing pricing analytics and decision tools into pharmaceutical and medical device companies to help drive improvements in company’s bottom line.

Ted joined LatticePoint in July 2016 and provides advisory services to early-stage companies in the cell and gene therapy space and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships. Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU. Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles. Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert. He was appointed as an Independent Director of Promethera Biosciences (BE) in April 2019. He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.

Karin joined LatticePoint in August 2019. She holds a PhD in Biology obtained from the University of Hamburg, Germany.

Prior to consulting, Karin performed fundamental and translational research in the fields of infectious, autoimmune and neurodegenerative diseases. During her scientific career, she led several research projects, including the development of new animal models for autoimmune diseases and research of new strategies to prevent viral infections. Her research contributed to the identification of new drug targets for the treatment of multiple sclerosis, which are now in development. She has contributed to patent applications, obtained prestigious awards for her research and authored several high-impact publications.

Heinz joined LatticePoint in January 2016. He is responsible for the retained payer panel database with a large collection of key stakeholders ranging from payers, prescribers, HTA advisors to medical key opinion leaders in US, Europe and parts of Asia. He focuses on the Market Access and Reimbursement system of the German speaking countries and has hands-on experience with AMNOG reimbursement dossiers and AMNOG exemption for inpatient products. He is also responsible for the pricing database and has conducted several pricing assessments projects as well as developed market forecast Excel models based on epidemiology or market sales.

Heinz received his M.Sc. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. During his studies, he was working on various academic projects covering subjects from computational molecular biology, development biology, diabetes to biomaterials, stem cells and radiology

Sanja  joined LatticePoint in September 2021. Sanja holds a regulatory affairs certificate: Pharmaceuticals, issued by RAPS and has supported clients in bridging their regulatory and market access strategies. Sanja has experience in the development of strategies to maintain orphan drug designations at marketing authorization and the development of value-based communication materials.

Sanja holds a Ph.D. in Theoretical Physical and Computational Chemistry obtained from the ETH, Zurich. She started her career in 2008 as a Scientist in one of the world’s leading specialty chemical companies. During her career, Sanja transitioned from olfaction research to the business unit. Sanja’s most recent role as Director in Innovation was to connect fundamental R&D, IT, and Business divisions in order to speed-up innovation to market. She worked closely with commercial and marketing teams and supported clients’ requests. Sanja holds also obtained an IPMA project management certification.

Benjamin joined LatticePoint in April 2022. He holds a PhD in Life Sciences from the University of Lausanne (Switzerland).

Benjamin has a research background in cancer immunotherapies using engineered T lymphocytes and dendritic cells.
Prior to joining LatticePoint, Benjamin worked as associate scientist at Debiopharm International and was project leader at Transcure bioServices, where he oversaw in vivo immune-oncology studies for international pharmaceutical clients.

During her PhD, she carried out different projects focusing on behavioral biases in economic decision making. In particular, she investigated the impact of overconfidence on negotiation outcomes, experimentally and by means of theoretic models. Moreover, in her early researcher experience, she explored economic market dynamics in agent-based models empirically parametrized.

Benedetta joined LatticePoint in July 2022. She holds a M.Sc. in Pharmaceutical Chemistry from the University of Trieste (Italy) and a Marie-Curie joint-PhD in Pharmaceutical Sciences between the University of Basel (Switzerland) and University of Ljubljana (Slovenia).

During her scientific carrier, she specialized in the field of medicinal chemistry. She carried out her master thesis with an Erasmus fellowship at the University Complutense in Madrid, where she worked on the development of inhibitors of the bacterial protein FtsZ. In December 2021, Benedetta obtained a PhD in the field of carbohydrate chemistry. In particular, her project was focused on the design, synthesis, and biological evaluation of potent glycomimetic ligands for Siglec-8, a promising pharmacological target for the treatment of eosinophils and mast cells-associated diseases.

Estelle has a research background in Neurovascular diseases and thrombolysis. She worked on developing a new thrombolytic agent to be used in stroke. Before joining LatticePoint, Estelle worked as an MSL for HRA Pharma and as a research associate for Op2Lysis, where she oversaw the development of research protocol and preclinical development.